United States · Series A startup

Who invested in Empire Genomics

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 31 Oct 2026

$1.0Mraised across 1 round since 2014, from 1 source

Latest round
Series A, $1.0MJul 2014
Investors
1
See who backed them

The rounds

  1. Jul 2014
    Series A$1.0M

    From a historical funding recordSEC filing: $1.0M sold, first sale Jun 2014

Founders and team

From the SEC filings it signed: 2 on the team.

  • Aaron FisherExecutive Officeri
  • William SniderExecutive Officer, Director, Promoteri

Everyone who backed them

Rand CapitalVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Empire Genomics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

BroadOak Capital PartnersVC firmPer its own site

Quick answers about Empire Genomics

Who invested in Empire Genomics?

Empire Genomics's investors include Rand Capital.

How much has Empire Genomics raised?

Empire Genomics has raised $1.0M across 1 round since 2014.

When did Empire Genomics last raise?

Empire Genomics's most recent round was a Series A of $1.0M in Jul 2014.

What was Empire Genomics's biggest round?

Its most recent round, $1.0M in Jul 2014, is also its largest on record.

Who backed Empire Genomics first?

Empire Genomics's first round on record, in Jul 2014, was backed by Rand Capital.

What stage is Empire Genomics at?

Empire Genomics's latest named round is a Series A, in Jul 2014.

Where is Empire Genomics based?

Empire Genomics is based in the United States.

Companies like Empire Genomics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.